Upstream Clopidogrel Use and the Efficacy and Safety of Early Eptifibatide Treatment in Patients With Acute Coronary Syndrome An Analysis From the Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) Trial
Wang, Tracy Y × White, Jennifer A Tricoci, Pierluigi Giugliano, Robert P Zeymer, Uwe Harrington, Robert A Montalescot, Gilles James, Stefan K Van de Werf, Frans Armstrong, Paul W Braunwald, Eugene Califf, Robert M Newby, L. Kristin #
Lippincott Williams & Wilkins
Circulation vol:123 issue:7 pages:722-730
Background-In the Early Glycoprotein IIb/IIIa Inhibition in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial, routine preangiography eptifibatide use was not superior to delayed provisional use but led to more bleeding. This analysis examines efficacy and safety of early eptifibatide in the setting of concurrent upstream clopidogrel use.